MWAS+ – A Novel Drug Repurposing Strategy for ADRD Prevention

MWAS — 预防 ADRD 的新型药物再利用策略

基本信息

  • 批准号:
    10446705
  • 负责人:
  • 金额:
    $ 76.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-15 至 2027-05-31
  • 项目状态:
    未结题

项目摘要

Nearly 6 million Americans ≥65 years suffer from Alzheimer’s disease (AD) or AD-related dementias (ADRD). AD/ADRD poses significant emotional, physical, and financial burdens on patients, families, and societies. There is no cure for AD/ADRD, and apart from the June 2021 controversial “accelerated approval” of aducanumab, no new symptom-modifying drug has been approved since 2003, highlighting the need for AD/ADRD prevention. Currently, no drug is available to delay the onset of AD/ADRD. The prohibitive cost of developing new drugs or repositioning partially developed drugs for AD/ADRD treatment would be even more prohibitive for AD/ADRD prevention as the latter would require larger sample size and longer follow-up. An alternative cost-effective and efficient approach is to repurpose from >20,000 FDA-approved drugs for AD/ADRD prevention. However, repurposing of drugs is often accidental. A timely and purposeful discovery of new clinical benefits of old drugs requires a systematic examination of large comprehensive clinical databases with longitudinal records and long follow-up, using innovative, sophisticated mixed machine learning and statistical tools. This application has been prepared in response to the NIA PAR-20-156 entitled “Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer’s Disease”. We propose a 3-Step Medication-Wide Association Study Plus (MWAS+) approach. Our MWAS+ will employ innovative explainable deep (machine) learning, a powerful artificial intelligence tool for noisy, nonlinear data. We will use Veterans Affairs (VA) electronic health record (EHR) data of >3 million Veterans ≥65 years (54,411 women; 202,000 African American), ~600 prescription drugs (each used by ≥10,000 Veterans), ≥10 years of history and ~200,000 AD/ADRD cases. In Step 1 (Aim 1), we will conduct a hypothesis-free exploratory case-control MWAS (akin to GWAS) to identify drugs associated with AD/ADRD in the VA EHR data. Drugs identified in Aim 1 will be reviewed by a panel of experts for plausible mechanistic pathways and 10 drugs will be recommended for hypothesis testing in Step 2 using VA EHR data (Aim 2) and external validation in Step 3 using Medicare data (Aim 3). In Aims 2 and 3, we will conduct outcome-blinded cohort studies using new user design. Marginal structural models and other causal inference methods, including doubly-robust inference procedures, will be used to estimate time- fixed (“intent-to-treat”) and time-varying (“as-treated”) effects of those drugs on incident AD/ADRD. The proposed project is highly significant because it will rigorously accelerate the identification of already approved drugs that have a high potential to be repurposed to delay and prevent AD/ADRD, a rapidly growing public health crisis. The project is innovative as it combines state-of-the-art deep learning and statistical methods to conduct an MWAS+ study that has never been used before for AD/ADRD prevention. In addition, the VA EHR contains high quality clinical data including pharmacy fill records and rich phenotypic information including fitness and frailty. Findings from this project will inform future clinical trials to repurpose approved drugs for AD/ADRD prevention.
近600万65岁以上的美国人患有阿尔茨海默病(AD)或AD相关痴呆(ADRD)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALI AHMED其他文献

ALI AHMED的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALI AHMED', 18)}}的其他基金

Understanding CNS Stimulant Use and Safety in Veterans with TBI
了解患有 TBI 的退伍军人的中枢神经系统兴奋剂使用和安全性
  • 批准号:
    10538168
  • 财政年份:
    2023
  • 资助金额:
    $ 76.41万
  • 项目类别:
MWAS+ – A Novel Drug Repurposing Strategy for ADRD Prevention
MWAS — 预防 ADRD 的新型药物再利用策略
  • 批准号:
    10677666
  • 财政年份:
    2022
  • 资助金额:
    $ 76.41万
  • 项目类别:
Magnesium supplement and vascular health: Machine learning from the longitudinal medical record
镁补充剂和血管健康:从纵向病历中进行机器学习
  • 批准号:
    10301239
  • 财政年份:
    2021
  • 资助金额:
    $ 76.41万
  • 项目类别:
Magnesium supplement and vascular health: Machine learning from the longitudinal medical record
镁补充剂和血管健康:从纵向病历中进行机器学习
  • 批准号:
    10489843
  • 财政年份:
    2021
  • 资助金额:
    $ 76.41万
  • 项目类别:
Magnesium supplement and vascular health: Machine learning from the longitudinal medical record
镁补充剂和血管健康:从纵向病历中进行机器学习
  • 批准号:
    10672376
  • 财政年份:
    2021
  • 资助金额:
    $ 76.41万
  • 项目类别:
Improving Outcomes in Veterans with Heart Failure and Chronic Kidney Disease
改善患有心力衰竭和慢性肾脏病的退伍军人的预后
  • 批准号:
    10186538
  • 财政年份:
    2019
  • 资助金额:
    $ 76.41万
  • 项目类别:
Neurohormonal Blockade and Outcomes in Diastolic Heart Failure
舒张性心力衰竭的神经激素阻断和结果
  • 批准号:
    7929469
  • 财政年份:
    2009
  • 资助金额:
    $ 76.41万
  • 项目类别:
Neurohormonal Blockade and Outcomes in Diastolic Heart Failure
舒张性心力衰竭的神经激素阻断和结果
  • 批准号:
    7699418
  • 财政年份:
    2009
  • 资助金额:
    $ 76.41万
  • 项目类别:
Heart failure, chronic kidney disease, and renin-angiotensin system inhibition
心力衰竭、慢性肾脏疾病和肾素-血管紧张素系统抑制
  • 批准号:
    7837545
  • 财政年份:
    2009
  • 资助金额:
    $ 76.41万
  • 项目类别:
Heart failure, chronic kidney disease, and renin-angiotensin system inhibition
心力衰竭、慢性肾脏疾病和肾素-血管紧张素系统抑制
  • 批准号:
    7433751
  • 财政年份:
    2006
  • 资助金额:
    $ 76.41万
  • 项目类别:

相似海外基金

Broadening Participation Research: Understanding faculty attitudes, competency, and perceptions of providing career advising to African American STEM students at HBCUs
扩大参与研究:了解教师对 HBCU 的非裔美国 STEM 学生提供职业建议的态度、能力和看法
  • 批准号:
    2306671
  • 财政年份:
    2023
  • 资助金额:
    $ 76.41万
  • 项目类别:
    Continuing Grant
Cognitive Behavioral Faith-based Depression Intervention For African American Adults (CB-FAITH): An Effectiveness And Implementation Trial
非裔美国成年人基于认知行为信仰的抑郁干预 (CB-FAITH):有效性和实施试验
  • 批准号:
    10714464
  • 财政年份:
    2023
  • 资助金额:
    $ 76.41万
  • 项目类别:
DELINEATING THE ROLE OF THE HOMOCYSTEINE-FOLATE-THYMIDYLATE SYNTHASE AXIS AND URACIL ACCUMULATION IN AFRICAN AMERICAN PROSTATE TUMORS
描述同型半胱氨酸-叶酸-胸苷酸合成酶轴和尿嘧啶积累在非裔美国人前列腺肿瘤中的作用
  • 批准号:
    10723833
  • 财政年份:
    2023
  • 资助金额:
    $ 76.41万
  • 项目类别:
Preventing Firearm Suicide Deaths Among Black/African American Adults
防止黑人/非裔美国成年人因枪支自杀死亡
  • 批准号:
    10811498
  • 财政年份:
    2023
  • 资助金额:
    $ 76.41万
  • 项目类别:
Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness-based Stress Reduction for Justice-Involved Black/African American Female Adolescents and Parents/Caregivers
探索创伤后应激障碍 (PTSD) 症状、障碍和促进因素,为涉及正义的黑人/非裔美国女性青少年和父母/照顾者进行基于正念的减压
  • 批准号:
    10593806
  • 财政年份:
    2023
  • 资助金额:
    $ 76.41万
  • 项目类别:
BCSER - PVEST: A Dynamic Framework for Investigating STEM Interest, Attitude and Identity Among African American Middle School Students
BCSER - PVEST:调查非裔美国中学生 STEM 兴趣、态度和身份的动态框架
  • 批准号:
    2327055
  • 财政年份:
    2023
  • 资助金额:
    $ 76.41万
  • 项目类别:
    Standard Grant
Making the Connection: Understanding the dynamic social connections impacting type 2 diabetes management among Black/African American men
建立联系:了解影响黑人/非裔美国男性 2 型糖尿病管理的动态社会联系
  • 批准号:
    10782674
  • 财政年份:
    2023
  • 资助金额:
    $ 76.41万
  • 项目类别:
Building a Community-Based Mental Health Literacy Intervention for African American Young Adults
为非裔美国年轻人建立基于社区的心理健康素养干预措施
  • 批准号:
    10738855
  • 财政年份:
    2023
  • 资助金额:
    $ 76.41万
  • 项目类别:
African American Literature in "post" Post-Racial America
“后”后种族美国中的非裔美国文学
  • 批准号:
    23K00376
  • 财政年份:
    2023
  • 资助金额:
    $ 76.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Impact of a Race-Based Stress Reduction Intervention on Well-Being, Inflammation, and DNA methylation in Older African American Women at Risk for Cardiometabolic Disease
基于种族的减压干预措施对有心血管代谢疾病风险的老年非洲裔美国女性的健康、炎症和 DNA 甲基化的影响
  • 批准号:
    10633624
  • 财政年份:
    2023
  • 资助金额:
    $ 76.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了